About

ReGenesys BVBA is a biotechnology company in Leuven, Belgium, that is focused on the research and development of stem cell-based therapies. ReGenesys is a wholly-owned subsidiary of Athersys, Inc. (NASDAQ: ATHX), a biotechnology company in Cleveland, Ohio, U.S.A., that is developing its MultiStem® cell therapy, a patented, adult-derived, “off-the-shelf” stem cell product initially for disease indications and conditions in the neurological, cardiovascular, inflammatory and immune areas.  Athersys has several ongoing clinical trials to evaluate its MultiStem product candidate.

ReGenesys is focused on the research and development of the multipotent adult progenitor cell (MAPC®) cell therapy technology, which is the basis for the MultiStem platform, and performs various preclinical studies and core research to further advance the technology. ReGenesys has extensive experience in areas such as cell expansion, cell characterization and potency assays, as well as scientific and process development knowledge that supports Athersys’ MultiStem clinical programs. ReGenesys has filed multiple patent applications related to its discoveries and is developing potential new regenerative medicine opportunities, such as animal health care.  ReGenesys collaborates with leading academic institutions and other biotechnology companies to further advance its programs.

ReGenesys’ expertise has been built out over the years and has resulted in the completion of a xenobiotic-free stem cell isolation, expansion and cryopreservation platform for the stem cell products.  ReGenesys has optimized use of the Quantum bioreactor for stem cell expansion. Also, ReGenesys has built a strong expertise in stem cell research, molecular and functional characterization, potency testing assays and ’omics-based’ comparability screening and xenobiotic-free stem cell-based process and product development. A potential product similar to MultiStem has been developed by ReGenesys for the veterinary market. Being a member of a regional network for innovative regenerative medicine (RegMed), ReGenesys has a strong focus on tissue engineering and next generation stem cell product development.